British Journal of Haematology最新文献_第8页

Immortal time bias limits the conclusion that post-transplant hypomethylating agent maintenance improves outcomes in myelodysplastic syndromes. 不朽的时间偏差限制了移植后维持低甲基化药物改善骨髓增生异常综合征结局的结论。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-10-01 Epub Date: 2026-07-05 DOI: 10.1111/bjh.70669

Naif I AlJohani

引用次数: 0

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-10-01 Epub Date: 2026-07-29 DOI: 10.1111/bjh.70724

Velizar Shivarov

引用次数: 0

Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study. Danburstotug是一种抗pd - l1抗体，用于治疗复发/难治性结外自然杀伤/ t细胞淋巴瘤：2期DISTINKT研究

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-10-01 Epub Date: 2026-08-18 DOI: 10.1111/bjh.70742

Won Seog Kim, Seok Jin Kim, Jae-Cheol Jo, Sang Eun Yoon, Youngil Koh, Deok-Hwan Yang, Dok Hyun Yoon, Junhun Cho, Sung Young Lee, Suyeon Kim, Seongyeon Kang, Woochan Hwang, Hyukjung Kim, Hwi-Yeol Yun, Jihyun Jeon, Chul Ahn, Heung Tae Kim

{"title":"Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.","authors":"Won Seog Kim, Seok Jin Kim, Jae-Cheol Jo, Sang Eun Yoon, Youngil Koh, Deok-Hwan Yang, Dok Hyun Yoon, Junhun Cho, Sung Young Lee, Suyeon Kim, Seongyeon Kang, Woochan Hwang, Hyukjung Kim, Hwi-Yeol Yun, Jihyun Jeon, Chul Ahn, Heung Tae Kim","doi":"10.1111/bjh.70742","DOIUrl":"10.1111/bjh.70742","url":null,"abstract":"Relapsed/refractory extra-nodal natural killer/T-cell lymphoma (R/R ENKTL) has limited treatment options. Danburstotug, an antibody targeting programmed death-ligand 1 (PD-L1), was evaluated in adults with R/R ENKTL in a phase 2, open-label study (NCT04414163). Danburstotug 20 mg/kg was administered intravenously every 2 weeks up to 52 cycles, disease progression or unacceptable toxicity. In the full analysis set (n = 19), objective response rate (ORR; primary end-point) was 78.9% (95% confidence interval 54.4-94.0); complete response (CR) rate was 63.2% (38.4-83.7); 76.9% of participants maintained responses; and 90.9% of participants maintained CR for 2 years. In the intention-to-treat population (n = 23), median progression-free survival (PFS) was 29.4 months (12.0-46.9; 2-year PFS rate 62.1%); and median overall survival was 40.2 months (25.1-55.4; 2-year overall survival rate 77.9%). Treatment-emergent adverse events occurred in 91.3% of 23 participants (73/83 events were grade 1/2); grade 3 serious treatment-related adverse events comprised liver injury and uveitis (one participant each). High PD-L1 membrane specificity (MS) was associated with greater ORR, CR rate and PFS versus low PD-L1 MS. In tumour immune microenvironment assessments, clinical benefit was observed across immune tolerance and immune evasion subtypes, despite lower PD-L1 expression in immune evasion-B. Danburstotug demonstrated robust, durable efficacy and manageable safety. PD-L1 MS showed potential as a predictive biomarker.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1638-1650"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peripheral blood clonal T-cell receptor rearrangements are associated with higher M-protein levels in newly diagnosed plasma cell dyscrasias. 外周血克隆t细胞受体重排与新诊断的浆细胞异常中较高的m蛋白水平相关。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-10-01 Epub Date: 2026-08-14 DOI: 10.1111/bjh.70755

Zhihong Jiang, Yuxin Zhang, Boning Niu, Yating Jiang, Xiaona Wang, Yangyang Wang, Danxia Lin, Zheng Wei

引用次数: 0

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma. 调整给药，更强的结果：Selinexor治疗适应和定位先前治疗的多发性骨髓瘤。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-10-01 Epub Date: 2026-07-21 DOI: 10.1111/bjh.70711

Muhamed Baljevic

{"title":"Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma.","authors":"Muhamed Baljevic","doi":"10.1111/bjh.70711","DOIUrl":"10.1111/bjh.70711","url":null,"abstract":"In patients with lenalidomide-refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs. 11.1%), longer duration of response (15.3 vs. 4.2 months), longer time to next treatment (14.8 vs. 4.8 months) and longer progression-free survival (13.9 months vs. 5.1 months). Selinexor dose reduction further improved tolerability, enabling longer treatment duration, with non-haematological adverse events such as nausea, fatigue, diarrhoea, decreased appetite and vomiting all decreased meaningfully after the first SEL dose reduction. Quality of life improved meaningfully also: global health status quality assessed via European Organization for Research and Treatment of Cancer Quality of Life Questionnaire improved more than twice as much in the SEL-reduced group versus the full-dose group, with the dose-reduced patients exceeding the clinically meaningful 10-point improvement threshold after dose reduction. Commentary on: Delimpasi et al. Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial. Br J Haematol 2026; 208:2260-2264.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1970-1973"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13674197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype. 慢性淋巴细胞白血病和复杂核型患者的最小残留疾病引导依鲁替尼和维托克拉克斯。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-10-01 Epub Date: 2026-08-19 DOI: 10.1111/bjh.70761

Maria Kislova, Elena Dmitrieva, Elena Naumova, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva, Tatiana Obukhova, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin

{"title":"Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.","authors":"Maria Kislova, Elena Dmitrieva, Elena Naumova, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva, Tatiana Obukhova, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin","doi":"10.1111/bjh.70761","DOIUrl":"10.1111/bjh.70761","url":null,"abstract":"Complex karyotype (CK) is a strong predictor of early progression and poor survival in chronic lymphocytic leukaemia (CLL), including during targeted therapy. Minimal residual disease (MRD)-guided therapy may improve outcomes by enabling deeper remissions and limiting clonal evolution. We present the final results of a prospective MRD-guided ibrutinib and venetoclax (IVen) compared with a retrospective cohort treated with ibrutinib monotherapy (Imono). Eligible patients had CLL with high CK (≥5 aberrations) or CK with deletion 17p. The IVen cohort received 3 months of ibrutinib followed by up to 24 months of IVen combination therapy or until three consecutive undetectable MRD (uMRD) bone marrow assessments. Patients with detectable MRD after 24 months continue ibrutinib alone. Baseline characteristics showed numerical differences between cohorts that did not reach statistical significance. A total of 106 patients were included (IVen n = 50; Imono n = 56). With a median follow-up of 42.1 months, IVen significantly improved progression-free survival (PFS) (33.9 months vs. NR; hazard ratio [HR] 0.23, p < 0.001) and overall survival (OS) (47 months vs. NR; HR 0.48, p = 0.0186) compared with Imono, although comparisons are limited by the retrospective control design. uMRD was achieved in 66% of patients with IVen. These results support MRD-adapted IVen as an optimal strategy for high-risk CLL.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1664-1672"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13674212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022. 细胞遗传学异常对2016年至2022年EBMT中心接受AHSCT的del（17p）骨髓瘤患者预后的累积影响。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-10-01 Epub Date: 2026-08-19 DOI: 10.1111/bjh.70759

Claire Comerford, Patrick J Hayden, Diderik-Jan Eikema, Linda Koster, Sandra Sauer, Annoek Broers, Neil Rabin, Jean Noel Bastie, Tobias Gedde-Dahl, Luisa Giaccone, Deborah Richardson, Kristina Carlson, Britta Besemer, Jean-Marc Schiano de Colella, Robert Zeiser, Laure Vincent, Thomas Pabst, Anne Cairoli, Christine Schuermans, Monica Poiani, Kavita Raj, Joanna Drozd-Sokolowska, Laurent Garderet, Inas El Najjar, Meral Beksac, Donal P McLornan

引用次数: 0

Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial. 艾加替莫德IV对原发性免疫性血小板减少症患者未成熟血小板分数的影响

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-10-01 Epub Date: 2026-08-16 DOI: 10.1111/bjh.70749

Hanny Al-Samkari, Filip Matthijssens, Kaichi Nishiwaki, Francesco Zaja, Sylvian Audia, Yoshitaka Miyakawa, Jaume Ayguasanosa, Damien Chimits, Anna Hultberg, Peter Ulrichts

引用次数: 0

Venetoclax-enhanced reduced-intensity conditioning in older patients aged ≥55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study. 在接受同种异体外周血干细胞移植的年龄≥55岁的高危髓系恶性肿瘤患者中，venetoclax增强的降低强度调节：一项II期研究

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-10-01 Epub Date: 2026-07-15 DOI: 10.1111/bjh.70690

Jie Gao, Huiying Qiu, Yin Tong, Chongmei Huang, Baoxia Dong, Jiahua Niu, Kun Zhou, Yu Cai, Liping Wan, Xianmin Song, Jun Yang

{"title":"Venetoclax-enhanced reduced-intensity conditioning in older patients aged ≥55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study.","authors":"Jie Gao, Huiying Qiu, Yin Tong, Chongmei Huang, Baoxia Dong, Jiahua Niu, Kun Zhou, Yu Cai, Liping Wan, Xianmin Song, Jun Yang","doi":"10.1111/bjh.70690","DOIUrl":"10.1111/bjh.70690","url":null,"abstract":"Reduced-intensity conditioning (RIC) is associated with a high relapse rate in high-risk acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). It remains unclear whether venetoclax, an anti-leukaemic agent, can enhance RIC efficacy. A prospective, single-arm, phase 2 trial enrolled patients with high-risk AML or MDS, aged ≥55 years, who underwent allogeneic peripheral blood stem cell transplantation (allo-PBSCT). All patients received venetoclax-enhanced RIC (VEN-RIC), comprising venetoclax, busulfan, fludarabine, cytarabine and low-dose total body irradiation (TBI). Fifty patients (median age 62) were enrolled. At a median follow-up of 14.9 months, the 1-year progression-free survival (PFS) was 72.5%, while 1-year overall survival (OS) and graft-versus-host disease/relapse-free survival (GVHD/GRFS) were 73.8% and 56.9% respectively. The 1-year cumulative incidence of relapse and non-relapse mortality were 16.8% and 10.6%. The 180-day cumulative incidence of acute GVHD was 22.9%, while the 1-year cumulative incidence of chronic GVHD was 25.8%. Multivariable analysis showed TP53 mutation was the strongest predictor of worse OS, PFS and GRFS, as well as higher relapse. We conclude that VEN-RIC is feasible and associated with encouraging survival and a manageable safety profile, warranting confirmation in randomized studies.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1773-1782"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148454075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immature platelet fraction predicts differential platelet recovery trajectories in dengue fever: A longitudinal analysis. 未成熟血小板分数预测不同的血小板恢复轨迹在登革热：纵向分析。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-10-01 Epub Date: 2026-07-26 DOI: 10.1111/bjh.70719

Santosh Kumar Singh, Suman Kumar, P V Sreejith, Mehek Khanuja, Abhishek Kumar, Sandeep Kumar, Deepanjan Dey, Uday Yanamandra

{"title":"Immature platelet fraction predicts differential platelet recovery trajectories in dengue fever: A longitudinal analysis.","authors":"Santosh Kumar Singh, Suman Kumar, P V Sreejith, Mehek Khanuja, Abhishek Kumar, Sandeep Kumar, Deepanjan Dey, Uday Yanamandra","doi":"10.1111/bjh.70719","DOIUrl":"10.1111/bjh.70719","url":null,"abstract":"Dengue commonly causes thrombocytopenia, but platelet count alone may not reflect marrow thrombopoiesis. Immature platelet fraction (IPF) is a potential marker of platelet regeneration, though longitudinal data are limited. We thus aimed to evaluate whether Day 1 IPF predicts subsequent platelet recovery trajectory and to describe longitudinal trends in clinical, biochemical and platelet indices. This was a retrospective longitudinal analytical study conducted at a tertiary care hospital in Western Maharashtra, India. Six hundred and sixty-seven patients with confirmed dengue, with platelet count, IPF and World Health Organization (WHO) classification recorded on Day 1, with follow-up at Day 3 and 5. Log-transformed platelet counts at Day 3 and Day 5 were analysed using generalized least squares regression. Longitudinal changes were assessed using the Friedman test. Median age was 31 years, with 81.4% males. Platelet counts declined from 118 to 98 × 109/L (p = 0.0017), while IPF increased from 9.7% to 12.9% (p < 0.0001). Higher baseline IPF predicted faster platelet recovery (p < 0.0001). Continued platelet decline at Day 5 was lower in the high-IPF group than the low-IPF group (28.6% vs. 47.8%; Kruskal-Wallis p = 0.013). We thus conclude that IPF is a dynamic biomarker that predicts platelet recovery trajectory in dengue.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1828-1837"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148589596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0